针对本期业绩变化的主要原因，博瑞医药表示主要受流感趋势变化、竞争格局变化、客户阶段性商业需 求波动等影响，使得当期营业收入及产品毛利额减少，以及在建工程陆续完工转固带来计提折旧增加， 同时创新药等研发投入加大使得研发费用等期间费用同比有所增加。 北京商报讯（记者 丁宁）1月30日晚间，博瑞医药（688166）发布2025年业绩预告显示，经财务部门初 步测算，预计2025年实现归属净利润4130万元到6190万元，与上年同期相比将同比减少67.28%到 78.17%。 ...

（编辑 任世碧） 证券日报网讯 1月30日，博瑞医药发布2025年年度业绩预告称，公司预计2025年年度归属于母公司所有 者的净利润4，130万元到6，190万元，与上年同期（法定披露数据）相比将同比减少67.28%到 78.17%。 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2026-003 博瑞生物医药（苏州）股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 三、本期业绩变化的主要原因 2025 年公司归属于母公司所有者的净利润预计同比减少 67.28%到 78.17%， 归属于母公司所有者的扣除非经常性损益的净利润预计同比减少 86.21%到 1 97.62%，主要受流感趋势变化、竞争格局变化、客户阶段性商业需求波动等影响， 使得当期营业收入及产品毛利额减少，以及在建工程陆续完工转固带来计提折旧 增加，同时创新药等研发投入加大使得研发费用等期间费用同比有所增加。 公司聚焦代谢领域，通过前瞻性布局，公司在多靶点联合用药及创新给药频 率等关键方向储备了丰富且具有竞争力的产品管线，旨在为患者提供更全面、更 个性化的治疗方案与用药选择。公司在研项目取得诸多进展，截至本公告披露日 ...

南财智讯1月30日电，博瑞医药发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 4130万元—6190万元，同比预减67.28%—78.17%；预计2025年全年归属于上市公司股东的扣除非经常 性损益的净利润为430万元—2490万元，同比预减86.21%—97.62%。2025年公司归属于母公司所有者的 净利润预计同比减少67.28%到78.17%，归属于母公司所有者的扣除非经常性损益的净利润预计同比减 少86.21%到97.62%，主要受流感趋势变化、竞争格局变化、客户阶段性商业需求波动等影响，使得当 期营业收入及产品毛利额减少，以及在建工程陆续完工转固带来计提折旧增加，同时创新药等研发投入 加大使得研发费用等期间费用同比有所增加。 ...

博瑞医药公告称，预计2025年年度归母净利润4130万元到6190万元，同比减少67.28%到78.17%；扣非 净利润430万元到2490万元，同比减少86.21%到97.62%。主要因流感趋势、竞争格局、客户需求变化致 营收和毛利减少，在建工程转固折旧增加，研发投入加大。公司在研项目进展多，如BGM0504注射液2 型糖尿病和减重两项适应症国内III期临床已完成入组；口服BGM0504片剂中美开展一期临床等。不过 创新药尚处早期，商业化存不确定性。 ...

Core Insights - 博瑞医药 has made significant progress in clinical trials for multiple core innovative drugs, showcasing its strong research and development capabilities [1][2][3] Group 1: Key Products - BGM0504, a core candidate drug, shows potential for treating metabolic diseases by activating GIP and GLP-1 pathways, aiding in blood sugar control, weight loss, and treatment of non-alcoholic fatty liver disease (NASH) [1] - BGM0504 injection is advancing in clinical trials across multiple regions, including China and Indonesia, with positive results in phase III studies [1] - The oral formulation of BGM0504 has received IND approval in China and the U.S., with the first subject dosed, indicating steady progress in global development and future commercialization [1] - BGM1812, another core product, is a novel long-acting Amylin analog designed to promote weight loss through multiple mechanisms, including activating brain satiety pathways [2] - BGM1812 has received clinical trial approval in both China and the U.S., with the first clinical enrollment successfully completed, positioning 博瑞医药 to capture a key advantage in the global weight loss drug market [2] - The combination formulation BGM2102, which integrates the advantages of dual-target agonists and Amylin analogs, aims to address the treatment needs of severely obese and precision weight loss patients [2] Group 2: Research and Development - 博瑞医药 is advancing other research projects, including peptide-based hypoglycemic drugs, anti-tumor drugs, and innovative developments in immune diseases, all progressing according to research plans [2] - The company is also deepening its technical platform for complex formulations, such as inhalation drugs, laying a foundation for future product pipeline expansion [2] - 博瑞医药 adheres to compliance in research and development, ensuring that all clinical trials follow international standards and relevant laws, with a commitment to timely and accurate disclosure of project progress [3]

Core Viewpoint - The A-share market experienced fluctuations on January 22, with the Shanghai Composite Index rising by 0.14%. The innovative drug sector faced pressure, as evidenced by the decline of the Science and Technology Innovation Drug ETF Huatai (589120) by 1.51% by 15:00. However, the ETF saw a net inflow of funds totaling 27.7361 million yuan over the past three days, indicating a trend of buying on dips [1]. Group 1: Market Performance - The Science and Technology Innovation Drug ETF Huatai (589120) recorded a net inflow of 27.7361 million yuan over three days, showing a clear trend of increased buying despite market declines [1]. - By 15:00, the ETF's component stocks exhibited mixed performance, with notable gains from Kangxinuo at 1.81%, Baiaotai at 0.49%, and Haoyuan Pharmaceutical at 0.48%. Conversely, Yifang Bio fell over 6%, Rongchang Bio dropped over 4%, and Baili Tianheng decreased by over 3% [6]. Group 2: Industry Insights - According to the National Medical Insurance Administration, 76 innovative drugs are expected to be approved for market entry by the National Medical Products Administration by 2025, marking a record high and indicating a trend towards diversified innovative therapies in China [4]. - Donghai Securities predicts that the innovative drug sector is entering a new era, transitioning from a generics-dominated market (pre-2018) to a period of transformation (2018-2025) characterized by price reductions and increased R&D investments in innovative drugs. By 2026, innovative drugs are expected to dominate the pharmaceutical industry in China, supported by complementary insurance policies and a focus on the pace of new drug launches and competitive dynamics [5].

Group 1 - The China Securities Regulatory Commission (CSRC) has announced supplementary material requirements for 23 companies regarding their overseas issuance and listing [1][2][3] - Specific companies such as Huafu Technology and Shanjin International have been highlighted for particular concerns regarding shareholder relationships and safety production incidents [1][2][3] - The supplementary materials are aimed at ensuring compliance with regulations and addressing potential issues that may affect the companies' ability to list [1][2][3] Group 2 - Companies like Shichuang Securities and Zhineng Technology are required to clarify the status of state-owned shareholder identification and trust arrangements [2][3] - For Xiangdao Travel, there are inquiries about the actual operations of various services and whether necessary qualifications have been obtained [2][3] - Bo Rui Pharmaceutical is asked to provide details on its business operations related to health food sales and medical research, including necessary licenses [2][3] Group 3 - Guoxin Services must explain the status of significant litigation cases and their potential impact on future operations and the current issuance [3][4] - Hi Learning Network is required to clarify compliance with labor and social insurance regulations, as well as the status of pending lawsuits and administrative penalties [4][5] - Tian Nong Group needs to address compliance issues regarding animal husbandry licenses and environmental permits, which may pose significant legal risks [5][6] Group 4 - Companies like Fengjiang Management and Mingyu Pharmaceutical are required to provide legal opinions on their compliance with foreign investment regulations and the legitimacy of their capital structures [7][8][9] - Specific inquiries include the legitimacy of shareholding structures and the compliance of fundraising activities with regulatory requirements [7][8][9] - The focus is on ensuring that all companies meet the necessary legal and regulatory standards for their overseas listings [7][8][9]

证券代码：688166 证券简称：博瑞医药 公告编号：2026-002 转债代码：118004 转债简称：博瑞转债 博瑞生物医药（苏州）股份有限公司 关于不提前赎回"博瑞转债"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 自 2025 年 12 月 12 日至 2026 年 1 月 5 日，博瑞生物医药（苏州）股份 有限公司（以下简称"公司"）股票满足连续 30 个交易日中有 15 个交易日收盘 价格不低于当期转股价格的 130%（即 45.16 元/股），已触发《博瑞生物医药（苏 州）股份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"可 转债募集说明书"）中规定的有条件赎回条款。 公司于 2026 年 1 月 5 日召开第四届董事会第十七次会议，审议通过《关 于不提前赎回"博瑞转债"的议案》，决定本次不行使"博瑞转债"的提前赎回 权利，不提前赎回"博瑞转债"。 未来三个月内（即 2026 年 1 月 6 日至 2026 年 4 月 5 日期间），如"博瑞 转债"再次触发有条件赎回 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2026-001 转债代码：118004 转债简称：博瑞转债 博瑞生物医药（苏州）股份有限公司 可转债转股结果暨股份变动公告 未转股可转债情况：截至 2025 年 12 月 31 日，"博瑞转债"尚未转股的 可转债金额为 442,766,000 元，占"博瑞转债"发行总量的 95.2185%。 一、可转债发行上市概况 经中国证券监督管理委员会证监许可[2021]3551 号文同意注册，博瑞生物医 药（苏州）股份有限公司（以下简称"公司"）于 2022 年 1 月 4 日向不特定对 象发行 465 万张可转换公司债券，每张面值为人民币 100 元，发行总额 46,500.00 万元。本次发行的可转换公司债券的期限为自发行之日起六年，即 2022 年 1 月 4 日至 2028 年 1 月 3 日。 经上海证券交易所自律监管决定书[2022]22 号文同意，公司 46,500.00 万元 可转换公司债券于 2022 年 1 月 27 日起在上海证券交易所挂牌交易，债券简称"博 瑞转债"，债券代码"118004"。 根据有关规定和《博瑞生物医药（苏州）股份有限公 ...